MétaCan
Menu
Back to cohort
Record W4409994539 · doi:10.1001/jamaoncol.2025.0908

Modeling Population-Level Impacts of Cell-Free DNA Screening for Colorectal Cancer in Canada

2025· article· en· W4409994539 on OpenAlexaffabout
John M. Hutchinson, Yibing Ruan, Brendan J. Chia, Carl J. Brown, Robert J. Hilsden, Jonathan M. Loree, Darren R. Brenner

Bibliographic record

VenueJAMA Oncology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsSt. Paul's HospitalProvidence Health CareBC Cancer AgencyAlberta Health ServicesUniversity of Calgary
Fundersnot available
KeywordsMedicineColorectal cancerColonoscopyPopulationCell-free fetal DNACancerColorectal cancer screeningInternal medicineOncologyDemographyEnvironmental health

Abstract

fetched live from OpenAlex

Importance: Cell-free DNA (cfDNA) testing is an emerging approach for colorectal cancer screening that has been approved in the US. The impact of cfDNA testing in the Canadian setting, assuming adherence mirroring prior real-world cfDNA work and assay performance from a Guardant Health study, is unknown. Objective: To estimate how cfDNA screening impacts clinical and economic outcomes in Canada compared with existing screening approaches (fecal immunochemical testing [FIT] or colonoscopies). Design, Setting, and Participants: The OncoSim-Colorectal model (version 3.6.5.7) was used to simulate participation, relative effectiveness, and cost of introduction of cfDNA tests every 3 years. A population of 32 million Canadians were simulated and examined for outcomes and costs between 2024 and 2092. Exposures: Screening with colonoscopy, FIT, or cfDNA. Main Outcomes and Measures: Screen-detected colorectal cancer cases, deaths, health-adjusted person-years, potential years of life lost, and cost of cancer screening and management were examined. Results: Under higher participation, cfDNA detected 393 087 cases of colorectal cancer between 2024 and 2092 compared with 156 009 cases in the FIT scenario, and cfDNA reduced overall mortality by 121 383 deaths compared with current predictions with FIT. Linear regression models indicated that approximately 78% participation with 80% adherence or 69% participation with 100% adherence to cfDNA screening would be required to reduce deaths below the levels achieved by colonoscopy testing. Higher costs were associated with cfDNA testing, where each health-adjusted person-year had a cost of CAD $234.80 (US $164.06), and 0.025 deaths were averted per CAD $100 000 (US $69 874) additional dollars spent compared with FIT testing. When cfDNA testing was modeled with the same participation as FIT testing (43%), there was worse overall population impact (eg, greater number of deaths), emphasizing the importance of high participation for cfDNA testing to improve outcomes. Conclusions and Relevance: This study suggests that cfDNA testing could result in increased detection of colorectal cancer and reduced mortality if higher participation than reported in previous studies is achieved at the population level. Patient input on acceptance of blood-based vs stool-based screening may help inform real-world implementation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: Simulation or modeling
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.041
Threshold uncertainty score0.299

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.006
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0010.002
Science and technology studies0.0010.001
Scholarly communication0.0020.000
Open science0.0030.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.288
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJAMA OncologySame topicCancer Genomics and DiagnosticsFrench-language works237,207